The stan dard treat ment of lo cally ad vanced rec tal can cer in the United States is neoadjuvant chemoradiation, sur gi cal re sec tion with to tal mesorectal ex ci sion, and adjuvant che mo ther apy. In re cent years, a non-op er a tive ap proach has been sug gested for pa tients achiev ing a com plete clin i cal re sponse with chemoradiation alone to avoid the mor bid ity that ac com pa nies rad i cal exci sion. This ap proach is jus ti fied by the ob ser va tion that a sig nif i cant pro por tion of pa tients (15-40%) have achieved a patho log i cal com plete re sponse by the time of sur gery. We re view the most re cent lit er a ture to de ter mine if the oncologic out comes are com pa rable. We also dis cuss fu ture di rec tions in man age ment, in clud ing the con sol i da tion of che mo ther apy with neoadjuvant chemoradiation. Cur rently, dis tant recur rence rates ex ceed those of lo cal re cur rence and adjuvant che mo ther apy is of ten de layed pend ing postop er a tive re cov ery. Of fer ing che mo ther apy up-front would si mul ta neously treat both the pri mary tu mor and any micrometastatic dis ease with out de lay. A trial is cur rently un der way at our cen ter eval u at ing these treat ment mo dal i ties.
T he stan dard man age ment of lo cally ad vanced rec tal can cer (LARC) con sists of pre op er a tive chemora di ation, rec tal re sec tion with to tal mesorectal ex ci sion (TME), and adjuvant che mo ther apy. Neoadjuvant chemoradiation ther apy (CRT) pro vides ex cel lent rates of lo cal con trol, with up to 15-40% of pa tients ex hib it ing a patho log i cal com plete re sponse (pCR) at the time of surgery such that no re sid ual vi a ble tu mor cells are found on patho logic ex am i na tion of the sur gi cal spec i men. Those pa tients with a pCR have im proved oncologic out comes with lo cal re cur rence rates of less than 1% and a 5-year sur vival rate of over 95%, sug gest ing that there is a possi ble sub set of pa tients for whom a non-op er a tive manage ment (NOM) par a digm could be con sid ered. In pa tients who have achieved a pCR with CRT alone, the ben e fit of an op er a tion that does not re move any gross or mi cro scopic tu mor may not bal ance the risk of com pli cations, which can be as high as 20%. Pa tients could thus avoid, tem po rarily or al to gether, the sig nif i cant risks of rad i cal sur gery, which in clude bleed ing com pli ca tions, wound in fec tion, anastomotic leak, cre ation of a tem porary or per ma nent stoma, im paired bowel func tion, and nerve dam age lead ing to sex ual or uri nary dys func tion. In other words, cur ing the can cer with out re mov ing the rec tum could po ten tially de crease long-term func tional prob lems as above, and pre serve QoL. The pro por tion of LARC pa tients who have a patho logic com plete re sponse (pCR) af ter CRT have lower rates of tu mor re cur rence, and im proved sur vival, com pared to those who do not. This leads us to ques tion whether there is any ben e fit to re mov ing the rec tum in pa tients with a pCR.
The chal lenge cur rently lies in ac cu rately pre dict ing which pa tients will go on to have a pCR and thus may be el i gi ble for NOM. The "watch-and-wait" ap proach was first de fined, and has been sub se quently de scribed, in a se ries of ret ro spec tive stud ies by Habr-Gama in Brazil. Upon com ple tion of CRT, rather than pro ceed ing di rectly to sur gery, se lected pa tients with a com plete clin i cal response (cCR) were in stead closely fol lowed. Sal vage surgery was rec om mended at the first sign of lo cal re currence. Sim i lar out comes were noted be tween those patients ini tially man aged non-op er a tively and those who went on to rad i cal sur gery with a con firmed pCR. This was a com pel ling ob ser va tion that chal lenged a his tor i cal par a digm for LARC pa tients, and to date, an in creas ing num ber of re ports have yielded sim i lar re sults. These will be re viewed in this ar ti cle to bal ance the ev i dence. Ad di tion ally, the idea of con sol i dat ing CRT and systemic che mo ther apy prior to any sur gi cal con sid er ation would al low micrometastatic dis ease to be ad dressed preop er a tively. It would also im prove treat ment com pli ance by avoid ing de lay and/or with hold ing of adjuvant che mother apy due to com pli ca tions of sur gery. Spe cif i cally, more than one-third of el i gi ble pa tients never start adjuvant ther a peu tic reg i mens be cause they de velop post-op er a tive com pli ca tions, are too de bil i tated af ter sur gery, or sim ply re fuse treat ment; un for tu nately, less than half of el i gi ble pa tients re ceive the full course of FOLFOX.
Cur rent Lit er a ture
The sem i nal pa per by Habr-Gama ret ro spec tively reviewed re cords (1991-2002) of 265 pa tients with dis tal, resectable rec tal tu mors treated with pre op er a tive CRT. Ra di a tion (50.4 Gy) was de liv ered in 1.8 Gy frac tions for 6 weeks, with con com i tant fluorouracil or folinic acid on the first and last 3 days of ra dio ther apy. Pa tients were reeval u ated 8 weeks af ter com ple tion of CRT, and those with ev i dence of re sid ual tu mor un der went an op er a tion. cCR was de fined as the ab sence of re sid ual ul cer ation, mass, or mucosal ir reg u lar ity on clin i cal and en do scopic as sess ment, with whit en ing of the mu cosa and the presence of telangiectasias con sid ered ac cept able. Ra dio log ical im ag ing show ing no ev i dence of dis tant dis ease was also re quired.
Sev enty-one (27%) pa tients achieved an ini tial complete clin i cal and radiologic re sponse at the 8-week mark and were treated with out ini tial rad i cal sur gery. Sur veillance in this group in cluded monthly fol low-up vis its for the first year, and ev ery 2 and 6 months dur ing the second and third years, re spec tively, for dig i tal rec tal exam, proc tos copy, and CEA lev els. Radiologic im ag ing (CT, MRI, and/or ERUS) was per formed af ter 6 months and yearly there af ter. Adjuvant che mo ther apy was not offered to ei ther group in the ab sence of re cur rent dis ease.
Of 194 pa tients with an in com plete clin i cal re sponse who un der went re sec tion, 22 had a pCR and served as the com par i son group. Me dian fol low-up was 5 years. Lo cal re cur rence (LR) rates were 3% and 0% in the ob ser va tion and re sec tion groups, re spec tively; dis tant re cur rence (DR) rates were 4.2% and 13.6%. There was no sig nif icant dif fer ence be tween re cur rence and mor tal ity rates be tween groups. Five-year over all sur vival (OS) and disease-free sur vival (DFS) was 100% and 92% in the obser va tion group and 88% and 83% in the re sec tion group. Ten-year OS and DFS was 100% and 86% in the ob serva tion group. There was a small but sig nif i cantly higher 5-year sur vival rate in the ob ser va tion group, ac cord ing to Kaplan-Meier es ti mates (p = 0.01). The se ries was updated in 2006 to in clude 360 pa tients, with an ad di tional 28 hav ing a cCR. LR oc curred in an ad di tional 3 patients, and all were ame na ble to sal vage sur gery with no fur ther re cur rence. These data in di cate that an ini tial non-op er a tive ap proach of fered to care fully se lected patients yields sim i lar mor tal ity and re cur rence rates as those who un dergo sur gery and are found to have a pCR. The ex pe ri ence also sug gests that those pa tients who undergo NOM and do have a LR are ame na ble to sal vage sur gery.
Habr-Gama et al. later fur ther up dated and sum ma rized data from one of their two orig i nal hos pi tals. Out of 183 pa tients who un der went CRT be tween 1991 and 2011, 90 (49%) had ini tial cCR and were man aged non-op er atively. Of these, a to tal of 28 lo cal or pel vic re cur rences (31%) were doc u mented, with 71% oc cur ring within 18 months and the lat est at 64 months. Sal vage ther apy was pos si ble in 26 (93%). Of the two that were not ame na ble to sal vage ther apy, one ex pe ri enced con com i tant systemic re cur rence and the other had sig nif i cant med i cal comorbidities. Four pa tients ex pe ri enced fur ther re currence af ter sal vage ther apy, and were sub se quently managed in a pal lia tive man ner. Sys temic re cur rence occurred in a to tal of 13 (14%) pa tients. Over all, un der the watch-and-wait pro to col, 5-year OS and DFS were 91% and 68%. In this up dated se ries, OS was sim i lar to the rates ini tially re ported; how ever, DFS was lower. Of note, most re cur rences were iden ti fied rel a tively early, over half within the first 12 months, and the sal vage rate was high at 93%. In ter est ingly, in the pre vi ous two reports early re-growths (within 12 months of CRT) were con sid ered in com plete re sponses, as com plete re spond ers were only des ig nated as such if they had a sus tained response for 12 months. In the up dated se ries, early 
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re-growths were con sid ered as lo cal re cur rences rather than in com plete re spond ers, ac count ing for the in creased rate of cCR (Ta ble 1).
Maas et al. at Maastricht Uni ver sity de scribe data from 192 pa tients treated with CRT be tween 2004-2010, of which 21 (11%) had a cCR de ter mined at a mean of 6.5 weeks post-CRT. This was de fined as no re sid ual tu mor at en dos copy or only a small re sid ual erythematous ul cer or scar, neg a tive bi op sies from the scar, ul cer, or for mer tu mor lo ca tion, no pal pa ble tu mor af ter ini tially pal pa ble, and no sus pi cious lymph nodes on MRI. Adjuvant chemo ther apy was given to those with pos i tive nodal sta tus at pri mary stag ing. Twenty (10%) pa tients were found to have a pCR and func tioned as the com par i son group. No ta bly, 5 of these also had a sus pected cCR. Two-year OS and DFS was 100% and 89%, re spec tively, in the obser va tion group, with no sig nif i cant dif fer ence be tween that and the re sec tion group (Fig ure 1) . There was 1 LR in the ob ser va tion group, man aged with transanal ex cision. There were no LRs in the re sec tion group, but there were 2 deaths: one re lated to sur gi cal com pli ca tions as soci ated with co los tomy clo sure, and the other due to met astatic dis ease. This re port dem on strates a lower rate of cCR than the Habr-Gama se ries af ter CRT, but sim i lar rates of sur gi cal pa tients with a pCR. The rate of LR was lower than that sum ma rized in the Habr-Gama data; this may be re lated to the shorter fol low-up pe riod and/or the lower rate of pa tients se lected for NOM. Re gard less, these data sim i larly dem on strate com pa ra ble OS and DFS be tween pa tients se lected for NOM and those pa tients who had a pCR, as well as the fea si bil ity of suc cess ful sal vage sur gery.
At Me mo rial Sloan Kettering Can cer Cen ter (MSKCC), there have been an in creas ing num ber of patients man aged un der the "watch-and-wait" strat egy. We be gan im ple ment ing the "watch-and-wait" treat ment para digm in 2006. Re cent anal y sis from 2006 to 2010 identi fied 32 pa tients who had at tained a cCR af ter CRT and were man aged non-op er a tively. These pa tients re ceived ra di a tion doses be tween 4500-5600 cGy, and adjuvant che mo ther apy was given to 17 (53%). Pa tients were exam ined at 4-10 weeks post-CRT; cCR was de fined as no pal pa ble tu mor on dig i tal rec tal exam, and en dos copy show ing no vis i ble pa thol ogy other than a flat scar. The com par i son group con sisted of 57 pa tients who achieved a pCR af ter neoadjuvant CRT and rec tal re sec tion, with adjuvant che mo ther apy given to 50 (88%). At base line, those who were man aged non-op er a tively were older, had lower clin i cal stage, and had tu mors closer to the anal verge. Over all, there was a higher rate of LR in the ob ser va tion group than in the re sec tion group (21% and 0%, re spec tively) but sim i lar 2-year rates of DR (8% and 2%, re spec tively), DFS (88% and 98%, re spec tively), and OS (97% and 100%, re spec tively). The me dian time to LR was 11 months, and all were con trolled with sal vage re sec tion and TME, with no fur ther LR at me dian follow-up of 17 months. These data in di cated to us that a "watch-and-wait' treat ment par a digm could be car ried out in a safe fash ion and that, al though there was a higher rate of LR in the NOM group, sal vage rates and sur vival out comes were sim i lar to those treated with con ven tional CRT and sur gery.
Br A smaller ret ro spec tive study pub lished in 2013 from a ter tiary can cer cen ter in In dia an a lyzed two groups of patients with a cCR af ter CRT. The first group con sisted of 23 pa tients with a cCR who did not un dergo sur gery, and the sec ond group con sisted of 10 pa tients with a cCR who un der went elec tive sur gery. Seven (30%) pa tients in the ob ser va tion group de vel oped LR, com pared to none in the sur gi cal group. Me dian DFS and OS were 36 and 66 months in the ob ser va tion group, and 36 and 37 months in the sur gi cal group. This study dem on strates that while LR rates were higher with NOM, there was no det ri ment in terms of DFS or OS com pared to pa tients man aged op er a tively. How ever, this study does dif fer from the oth ers in that those in the sur gi cal com par i son group were also deemed to have a cCR and made a volun tary choice to un dergo sur gery.
In Eng land, an other small ret ro spec tive study (2004-2009) iden ti fied pa tients with a cCR af ter CRT. At 6 weeks post CRT, a re peat MRI was per formed to assess tu mor re sponse. If lit tle ev i dence of re sid ual dis ease was noted, an ex am i na tion un der an es the sia was un dertaken, with bi op sies of re sid ual scar tis sue. Any re sid ual mucosal ul cers were con sid ered to be tu mor, even if the bi op sies were be nign. Pa tients who still showed no ev idence of tu mor un der went FDG-PET scan ning, and if neg a tive were des ig nated as cCR. Of 49 pa tients who un der went CRT dur ing this time, 6 had a cCR and are dis ease-free to date, af ter a mean fol low-up of 25.5 months. With no lo cal re cur rences, this study dem onstrates the best out comes to date for NOM of LARC. No ta bly, this study ex am ined a smaller num ber of patients, with shorter mean fol low-up than the orig i nal Habr-Gama se ries. The se lec tion cri te ria were also more strin gent than those used in many of the other stud ies, uti liz ing both post-CRT MRI as well as bi opsy to de fine a cCR, and de fin ing all mucosal ul cers as tu mor.
In sum mary, these stud ies dem on strate that a "watch-and-wait" or non-op er a tive ap proach can be carried out safely with care ful se lec tion of pa tients, by the cli ni cian, in a pro spec tive fash ion. The pa tients who elect to un dergo NOM must be coun seled care fully, as this is non-stan dard prac tice out side of a clin i cal trial and car ries risks that should be care fully weighed. Re view of these data does im pli cate a num ber of small, ret ro spec tive in sti tu tional case se ries with vari able pa tient se lec tion and treat ment plans. Also, there is some vari abil ity in sur veil lance, fol low-up, de ter mi na tion of cCR, and use of im ag ing mo dal i ties, as well as clin i cal ex am i na tion, to iden tify re-growth or fail ure of non-op er a tive man agement.
DIS CUS SION
While the most re cent lit er a ture is prom is ing, and appears to in di cate that an ini tial non-op er a tive ap proach for se lect pa tients pro vides oncologic out comes that are at least sim i lar to those with a pCR treated by rad i cal resec tion (Ta ble 1), a lon ger-term pro spec tive study is clearly war ranted. A ran dom ized trial would prove dif ficult, as many pa tients may ob ject to ran dom iza tion to the op er a tive arm of such a study when a non-op er a tive approach is fea si ble. In Habr-Gama's se ries, none of the pa tients with a cCR asked for rad i cal sur gery in pref erence to the watch-and-wait ap proach . The cur rent published stud ies are rel a tively small, ret ro spec tive, and variable with re spect to def i ni tion of cCR, chemoradiation reg i mens, use of adjuvant che mo ther apy, and fol low-up pro to col. A larger pro spec tive study may also be ben e ficial by pro vid ing biopsied spec i mens to fur ther an a lyze the mo lec u lar pro files of tu mor re spond ers ver sus non-respond ers.
Given our ex pe ri ence with NOM and in duc tion che mother apy, our group is un der tak ing a multi-in sti tu tional, phase II ran dom ized con trolled trial eval u at ing 3-year DFS in pa tients with LARC. All pa tients will be treated pre op er a tively with both FOLFOX and long-course chemoradiotherapy (e.g. to tal neoadjuvant ther apy). By ran dom as sign ment, half will re ceive in duc tion FOLFOX (8 cy cles) fol lowed by chemoradiation; the other half will re ceive chemoradiation fol lowed by con sol i da tion FOLFOX (8 cy cles). The rates of clin i cal CR will be deter mined by en do scopic ex am i na tion and MR scan ning, and com pared for the two neoadjuvant arms. Pa tients who achieve cCR will be given the op tion of NOM. In ad di tion to eval u at ing suc cess in or gan pres er va tion, the study is also de signed to test the hy poth e sis that patients treated with to tal neoadjuvant ther apy and sur gery or non-op er a tive man age ment will have im proved 3-year DFS com pared to his tor i cal con trols treated with chemoradiotherapy, sur gery and adjuvant che mo ther apy. Ret ro spec tive anal y ses to date lend sup port to this approach, but we feel that a pro spec tive study will pro vide the data to fur ther sup port or re fute the ben e fit of to tal neoadjuvant ther apy.
When of fer ing a watch-and-wait ap proach, care ful selec tion of pa tients pre dicted to be patho logic com plete respond ers is of the up most im por tance. The pres ence of pCRs in the op er a tive group of the Habr-Gama se ries and the study by Maas et al. sug gests that the se lec tion cri teria used to iden tify cCRs at those in sti tu tions may slightly un der es ti mate the num ber of pCRs. Poor cor rela tion be tween cCR and pCR has been re ported by Hiotis et al. In that study, tu mors were resected within 6 weeks of chemoradiation, and thus may not have had ad e quate time to re spond. The sub tle ties of dig i tal rec tal ex am i nation alone could un der es ti mate the num ber of pCRs, as a re sult of lo cal in flam ma tion and fi bro sis in ter preted as tumor rem nant. The ques tion of whether cCR can ac curately pre dict pCR and the de vel op ment of stan dard ized guide lines to op ti mally iden tify such pa tients should be the goal of fu ture stud ies.
At our in sti tu tion, a two-stage as sess ment is used to iden tify po ten tial can di dates for non-op er a tive man agement. Pa tients are eval u ated with dig i tal rec tal ex am i nation and en do scopic vi su al iza tion at 6-7 weeks post-CRT af ter ini tial base line clin i cal as sess ment. Sur gery is recom mended for those pa tients with a suboptimal tu mor response. Pa tients with a con vinc ing cCR, noted as in vo lution of the tu mor to a pale, flat scar with al low able telangiectasias, may pro ceed to adjuvant che mo ther apy or sur veil lance. Those with min i mal ar eas of induration, nodularity, or ul cer ation are re as sessed at 10-12 weeks, al low ing more time for re gres sion. We have de vel oped a ma trix to better as sess re sponse in a stan dard way, and will re port on these find ings in the com ing year, add ing MR im ag ing to better de fine cCR in this set ting.
Other tools may as sist in the iden ti fi ca tion of cCR. For ex am ple, a post-CRT CEA level <5 is a sig nif i cant predic tor of cCR and im proved OS and DFS, in de pend ent of ini tial CEA level. The use of im ag ing may also serve as a prom is ing tool to more strin gently se lect cCRs. Maas et al. and Dal ton et al. both uti lized post-CRT MRI as part of the se lec tion cri te ria for a cCR, with ex cel lent re sults. Maas et al. noted only 1 LR out of 21 pa tients. All 6 patients from Dal ton et al. who were man aged non-op er atively have been dis ease-free. Other im ag ing mo dal i ties do not seem as prom is ing. For ex am ple, the pre dic tive value of endorectal ul tra sound (EUS) re-stag ing is only 47% in as sess ment of com plete re sponse. The weak ness of EUS lies in lim ited de tec tion of small tu mor re sid ing within fibrotic tis sue, and in over-stag ing sec ond ary to mis in ter pre ta tion of fi bro sis. FDG-PET and he li cal CT scan ning are sim i larly in ad e quate in dif fer en ti at ing complete and in com plete re sponses to chemoradiation.
As part of the multimodality treat ment ap proach to rectal can cers, the role and tim ing of che mo ther apy is also un der eval u a tion in both the op er a tive and non-op er a tive set ting. His tor i cally, dis tant re cur rence rates have exceeded those of lo cal re cur rence in LARC. The rate of nodal metastases in pa tients with a com plete tu mor response to CRT var ies from 0-7%. New dis tant met a static dis ease at the time of op er a tion with a pCR has been observed, and DR is also known to oc cur in pa tients with an ini tial pCR. At MSKCC, sev eral pa tients have been treated with up-front che mo ther apy, with the idea of simul ta neously treat ing the pri mary tu mor and any micrometastatic dis ease. This elim i nates the de lay that of ten ac com pa nies ini ti a tion of che mo ther apy af ter surgery, thus clos ing the win dow of time in which dis tant micrometastases may grow. Fur ther more, by al ter ing the se quence of treat ment in this way, the de liv ery of systemic che mo ther apy to the pri mary tu mor is op ti mized be cause the vasculature is un al tered by post-ra di a tion or sur gi cal changes. A ret ro spec tive re view of the pa tients treated in this man ner have dem on strated ex cel lent results. R0 re sec tions were achieved in 100% of pa tients who un der went sur gery, pCR was 27%, and 47% achieved greater than 90% re sponse. Treat ment was well-tol er ated, with no grade 4 tox ic i ties, and all pa tients were able to com plete the com bined CRT.
The clin i cal trial cur rently un der way at MSKCC will as sess some of these ques tions re gard ing op ti mi za tion of oncologic out comes and qual ity of life in pa tients with LARC. This Phase II trial will eval u ate dis ease-free events in pa tients with lo cally ad vanced rec tal can cer treated with CRT plus in duc tion or con sol i da tion che mother apy, fol lowed by ei ther TME or non-op er a tive manage ment. The trial will eval u ate the ef fi cacy and safety of non-op er a tive man age ment in the con text of mod ern chemo ther apy reg i mens de signed to ad dress the micrometastatic niche, while the pa tient can better tol erate the treat ment. In sum mary, these data in di cate that a "watch-and-wait" par a digm may be safe, yield sim i lar sal vage and sur vival ben e fits, and pre vent con sid er able mor bid ity and qual ity of life dif fi cul ties for many patients with LARC.
SUM MARY
RAZVOJNE PARADIGME LOKALNO UZNAPREDOVALOG KARCINOMA REKTUMA Standardni naèin leèenja uznapredovalog karcinoma rektuma u SAD je neoadjuvantna hemoradioterapija, totalna mezorektalna ekscizija i adjuvantna hemoterapija.
Da bi se izbegao morbiditet koji prati radikalnu eksciziju,poslednjih godina se sugerira ne-operativni pristup kod bolesnika koji su pokazali podpun klinièki odgovor posle samo hemoradioterapije. Ovaj stav je potvrðen zapažanjem da je znaèajan broj bolesnika (15-40%) postigao podpuni histopatološki odgovor u vreme operacije.
Prikazali smo najnoviju literaturu da bismo ustanovili uporedivost onkoloških rezultata. Takoðe, razmatramo buduaee pravce u leèenju, ukljuèujuaei konsolidaciju hemoterapije i neoadjuvantne hemoradioterapije.
Još uvek stopa udaljenih recidiva prevazilazi stopu lokalnih recidiva a adjuvantna hemoterapija je èesto odložena u oèekivanju postoperativnog oporavka.
Direktna hemoterapija, bez odlaganja, treba istovremeno da tretira primarni tu mor i eventualne mikrometastaze.
U našem centru je preduzeto istraživanje ovih terapijskih modaliteta.
Kljuène reèi: karcinom rektuma, neoperativni pristup, lokalno uznapredovali karcinom rektuma
Ab bre vi a tions: cCR = Clin i cal com plete re sponse, CRT = Chemoradiation ther apy, DFS = Dis ease-free sur vival, DR = Dis tant re cur rence, LARC = Lo cally ad vanced rec tal can cer, LR = Lo cal re cur rence, NOM = Non-op er a tive man age ment, OS = Over all sur vival, pCR = Patho logic com plete re sponse, TME = To tal mesorectal ex ci sion
